Denali Capital (NASDAQ:DECA) announced this morning that its shareholders approved its combination with biotech firm Longevity during a special meeting yesterday, January 9.
The deal was overwhelmingly approved as holders of 5,196,327 shares voted in favor of the proposal while holders of just 10,100 shares cast their votes against it.
In connection with the meeting, shareholders holding 4,440,202 public shares opted to redeem their shares. In total, Denali saw an aggregate of 98.82% of its trust removed from redemptions, including from previous extension votes, leaving it with around $1 million post-vote.
In August, Denali added $18 million in equity funding to its combination with Longevity through the sale of newly issued series A preferred shares to FutureTech Capital. But, the amount of shares purchased was later decreased in November from 1,800,000 to 1,300,000, reducing the funding to $13 million.
When announcing the business combination, Denali noted it aimed to raise a $30 million PIPE and that it must provide $30 million in cash in order for the deal to close. However, this closing cash condition was later waived.
The parties have not yet disclosed a timeline for the closing of the combination, but upon completion, the combined company is expected to trade on the Nasdaq under the symbol “LBIO”.
Denali Capital initially announced its $236.2 million combination with Longevity in January 2023. Bothell, Washington-based Longevity is building a platform to consolidate a number of clinical-stage therapies, beginning with treatment candidates aiming to improve outcomes of certain vascular conditions as well as replace lost tissue.
May is to extend a theme for the spring of 2025 with very few de-SPACs and sponsors coming free of their lock-up agreements. This is due in some cases to stellar performance but more broadly due to the slowdown in deal closings about 12 and six months ago. One way or the other, four sponsors...
At the SPAC of Dawn Now that earnings season is in full swing, more de-SPACs are set to provide updates on how both trade and market volatility are impacting their margins. On the positive side, USA Rare Earth (NASDAQ:USAR) has continued to reap the benefits from its position as one of few US-based producers of...
This week, we sit down with Rick Hendrix and Adam Fishman from the Live Oak SPAC team. Rick Hendrix is the Founder of Live Oak Merchant Partners, and Chairman and CEO of Live Oak Acquisition Corp. V (NASDAQ:LOKV). In addition, he is an operating executive at Crestview Partners, a New York-based middle market focused private equity firm....
Berto Acquisition Corp. (NASDAQ:TACOU) announced the pricing of its upsized $261 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TACOU”, Wednesday, April 30, 2025. The new SPAC aims to conduct a broad search for a target but will have a particular interest in artificial intelligence, wellness, longevity,...
Lakeshore Acquisition III Corp. (NASDAQ:LCCCU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “LCCCU”, Wednesday, April 30, 2025. The new SPAC aims to conduct a broad search for a target with a team that has previously closed business combinations in the...